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Abstract
Background—We explored the relationship between virologic response in the first year of 
treatment and long-term outcomes in the BENCHMRK studies.
Methods—Patients failing ART with 3-class resistant HIV-1 received double-blinded raltegravir 
(or placebo) with optimized background therapy (OBT) until week 156, then open-label raltegravir 
with OBT up to week 240. In this exploratory analysis of patients randomized to raltegravir, 
virologic response over weeks 16–48 was categorized as�continuous suppression (CS: vRNA 
always <50 copies/mL), low-level viremia�(LLV: vRNA always < 400 copies/mL; <50 
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copies/mL at least once), or not suppressed (NS: vRNA <400 copies/mL at least once). The 
association between these first-year vRNA response categories and baseline factors was analyzed 
with univariate and multivariate models. Virologic and immunologic outcomes for years 2–5 were 
assessed by first-year vRNA response category (observed failure approach).
Results—Baseline vRNA, baseline CD4 count, and rapid viral decay (vRNA <50 copies/mL 
between weeks 2–12) correlated with first-year vRNA response (p<0.001); only rapid viral decay 
remained significant by multiple regression. Virologic response rates were similar in the LLV and 
CS groups and lowest in the NS group. CD4 increased through week 240 in the CS and LLV 
groups. Time to loss of virologic response (confirmed vRNA ≥400 copies/mL) through Week 240 
did not support as strong a difference between the LLV and CS groups (log-rank p=0.11) as 
previously reported through Week 156 and 192 (p<0.05).
Conclusions—Treatment-experienced patients on a raltegravir-based regimen with early LLV 
may have long-term virologic and immunologic benefit when their therapy is maintained.
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INTRODUCTION
Raltegravir is an HIV-1 integrase strand-transfer inhibitor [1] approved for use in 
combination regimens for the treatment of HIV-1 infection in treatment-naïve and treatment-
experienced patients [2]. We have previously reported the final results of the combined 
BENCHMRK Phase III studies of raltegravir plus an optimized background regimen (OBT) 
in treatment-experienced patients infected with multi-drug resistant HIV-1 [3]. In the 
BENCHMRK studies, raltegravir with OBT demonstrated superiority over the control group 
of OBT plus placebo through 3 years of double-blind treatment. At week 48, approximately 
10% of patients in the raltegravir group had HIV RNA below 400 but greater than 50 
copies/mL [4]. According to current treatment recommendations, there is a lack of 
consensus on the management of patients with HIV-1 RNA levels between 50 and 200 
copies/mL [5]. The PLATO collaboration has shown that increases in CD4+ T-cell count 
can be achieved even when virus is not completely suppressed [6]. Several studies have 
shown that transient low-level viremia (vRNA between 50 and 400 copies/ml) has a limited 
effect on virologic and immunologic responses and on the development of drug resistance 
[7–10], while others have found that low-level viremia was associated with virologic failure 
and the emergence of drug resistance [11–14].
The predictors of and the long-term virologic and immunologic consequences of low-level 
viremia in the first year after initiation of therapy in highly treatment-experienced patients 
have not been described. Whether this pattern of response is associated frequently with 
subsequent virologic failure and resistance, as might be predicted, could influence treatment 
decisions. To gain a better understanding of the long-term clinical implications of low-level 
viremia, we explored the relationship between first-year vRNA response (at weeks 16–48) 
and long-term virologic and immunologic outcomes (from week 96 through week 240) 
among patients assigned to the raltegravir group in the BENCHMRK studies.
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BENCHMRK-1 (Protocol 018; NCT 00293267) and BENCHMRK-2 (Protocol 019; NCT 
00293254) were multicenter, double-blind, randomized, placebo-controlled studies to 
evaluate the safety, tolerability, and efficacy of raltegravir 400 mg b.i.d. compared with 
placebo, each in combination with OBT for 156 weeks [3,4]. After completing 156 weeks of 
double-blind therapy, patients were eligible to receive open-label raltegravir 400 mg b.i.d. 
plus OBT for an additional 84 weeks, for a total treatment duration of up to 240 weeks. The 
protocols were approved by the Institutional Review Board or Ethical Review Committee at 
each site, and all participants provided written informed consent.
HIV-seropositive patients who had failed prior antiretroviral therapy and had documented 
resistance to at least one protease inhibitor (PI), one nucleoside reverse transcriptase 
inhibitor, and one non-nucleoside reverse transcriptase inhibitor were enrolled at 61 sites in 
Europe, Asia, Australia, and Peru (BENCHMRK-1) and 53 sites in North and South 
America (BENCHMRK-2). Each patient’s OBT regimen was determined at study entry 
prior to randomization; the site investigator selected the best available combination of agents 
based on the patient’s antiretroviral treatment history, available drug-resistance testing, and 
laboratory data. Patients were randomly assigned in a 2:1 ratio to receive raltegravir 400 mg 
b.i.d. or matching placebo b.i.d. in addition to their OBT. Randomization was stratified by 
enfuvirtide use in OBT and degree of viral resistance to commercially available PIs. 
Investigators, study site and sponsor personnel, patients, and laboratory personnel remained 
blinded to treatment allocation until all patients had completed or discontinued the study, 
protocol violators had been identified, and data were declared complete.
HIV-1 RNA (vRNA) levels were measured by the standard COBAS Amplicor HIV-1 
Monitor™ assay (version 1.5; Roche Diagnostics, Branchburg, NJ; LLQ 400 copies/mL) 
and the Ultrasensitive Amplicor HIV-1 Monitor™ assay (version 1.5; Roche Diagnostics; 
LLQ 50 copies/mL) for samples with vRNA levels < 400 copies/mL by the standard assay. 
vRNA levels were measured at entry, every 4 weeks through week 16, every 8 weeks 
through week 48, and every 12 weeks thereafter. Resistance testing (PhenoSense GT™, 
Monogram Biosciences, San Francisco, CA) was performed at baseline and at the time of 
virologic failure.
Statistical Methods
These exploratory analyses utilized a modified-intention-to-treat (mITT) population. 
Patients were included in the treatment group to which they were randomized (provided they 
received at least one dose of study drug), regardless of adherence to the entry criteria, 
treatment actually received, and deviations from the protocol. The observed failure (OF) 
approach was used; only discontinuations due to lack of efficacy were counted as failures, 
and baseline values were carried forward for these patients.
Patients assigned to the raltegravir group who completed 48 weeks of double-blind 
treatment and continued in the study were categorized based on their observed vRNA 
response at five time points between weeks 16 and 48 (with no imputation for missing data) 
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as follows: continuous suppression (CS) was defined as vRNA <50 copies/mL at all time 
points; low-level viremia (LLV) was defined as vRNA < 400 copies/mL at all time points 
and <50 copies/mL at least once; and not suppressed (NS) was defined as vRNA <400 
copies/mL at least once. The association between these first-year vRNA response categories 
and the following prognostic factors was analyzed with univariate and multivariate models: 
baseline vRNA (≤100,000 vs <100,000 copies/mL), baseline CD4 cell count (≤50 vs <50 
cells/mm3, and ≤200 vs <200 cells/mm3), baseline genotypic sensitivity score (<2 vs ≥2), 
baseline phenotypic sensitivity score (<2 vs ≥2), and rapid viral decay, defined as vRNA 
<50 copies/mL at least once between weeks 2 and 12 (yes vs no). A k-by-k contingency 
table using each prognostic factor was constructed, and p-values were calculated by the 
Mantel-Haenszel chi-square test.
The following outcome measures were plotted for each of the first-year vRNA response 
categories: the proportion of patients with vRNA <50 copies/mL, the proportion with vRNA 
< 400 copies/mL, and the change from baseline in CD4 cell count (cells/mm3). Among 
patients with virologic failure, the proportion who developed integrase resistance-associated 
mutations was tabulated for the three vRNA response categories.
Kaplan-Meier curves were plotted for time to loss of virologic response (TLOVR) for the 
CS and LLV groups. For each patient, TLOVR was defined as the visit when vRNA 
exceeded 400 copies/mL and was subsequently confirmed (or the patient was discontinued); 
TLOVR was restricted to the first loss after week 48, which is the latest time point to 
determine the first-year vRNA response category. Cox regression was utilized to detect 
prognostic factors which could predict TLOVR; the prognostic factors mentioned above and 
the first-year vRNA response category (CS vs LLV) were included in this analysis.
By definition, patients in the LLV group could have had vRNA <50 copies/mL at a single 
time point or at multiple time points between weeks 16 and 48. To explore the impact of 
having one vs multiple vRNA responses in the LLV range (50–400 copies/mL), the LLV 
group was further divided into 2 subgroups: Group 1 (LLV1) included patients with only 
one vRNA response <50 copies/mL during weeks 16–48, and Group 2 (LLV2) included 
patients with multiple vRNA responses <50 copies/mL during the same period. The 
following analyses were repeated for the LLV1 vs LLV2 subgroups: virologic and 
immunologic responses over time, Kaplan-Meier curves for TLOVR, and Cox regression to 
detect factors predicting TLOVR (see above).
RESULTS
Of the 373 patients who completed 48 weeks of treatment with raltegravir, 199 (53%) were 
continuously suppressed during weeks 16–48, 111 (30%) had low-level viremia, and 63 
(17%) were not suppressed. Baseline vRNA levels were lowest among patients with 
continuous suppression and highest among those who were not suppressed, while baseline 
CD4 cell count, CD4%, CD8 cell count, and CD4/CD8 ratio were highest in the CS group 
and lowest in the NS group (Table 1). The CS and LLV groups had slightly more patients 
with at least one active PI in the OBT (65% and 69%, respectively) compared with the NS 
group (59%). Phenotypic sensitivity scores were similar for the CS and LLV groups (≥2 in 
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54% and 56%, respectively, vs 48% of the NS group), while genotypic sensitivity scores 
were similar for the LLV and NS groups (≥2 in 33%, vs 44% of the CS group). Rapid viral 
decay (vRNA <50 copies/mL at least once between weeks 2 and 12) was observed in 94% 
of the CS group, 64% of the LLV group, and 43% of the NS group. In the univariate 
analysis, baseline vRNA level, baseline CD4 count, and rapid viral decay were correlated 
with first-year vRNA response category (p<0.001), while genotypic and phenotypic 
sensitivity scores were not (p=0.072 and 0.592, respectively). In the multiple regression 
analysis, only rapid viral decay was significantly associated with first-year vRNA response 
category (p<0.001).
Long-term virologic response rates in the LLV group were similar to those in the CS group 
and were substantially higher than those in the NS group. At week 240, 80% of the CS 
group and 67% of the LLV group had vRNA < 50 copies/mL, compared with 21% of the NS 
group (Figure 1A). At the same time point, vRNA < 400 copies/mL was maintained in 85%, 
74% and 29% of the CS, LLV, and NS groups, respectively (Figure 1B). The mean change 
in CD4 cell count continued to increase in the CS and LLV groups, reaching 244 and 286 
cells/mm3, respectively, at week 240. In the NS group, the mean change in CD4 cell count 
peaked at 125 cells/mm3 at week 72 and remained relatively constant thereafter (Figure 1C).
Patients in the CS and LLV groups had higher rates of self-reported medication adherence 
than patients in the NS group (Table 2). Approximately 6% of patients in the CS group and 
12% in the LLV group discontinued treatment due to virologic failure or lack of treatment 
efficacy; substantially more patients in the NS group (44%) discontinued for these reasons 
(Table 3). Among patients�with virologic failure�between weeks 48 and 240 who had 
resistance testing performed, one or more�raltegravir signature mutations (AA 143, 148, or 
155) were�detected in 43% (9/21) from the CS group, 29% (4/14) from the LLV group, 
and 55% (26/47) from the NS group. Unlike prior analyses out to Week 156 (3 years) and 
Week 192 (4 years), the TLOVR analysis using data through Week 240 did not support as 
strong a difference (log-rank p=0.11) between the LLV and CS groups (Figure 2). 
Furthermore, none of the factors examined in the Cox regression analysis were significant 
predictors of TLOVR, including initial rapid viral decay.
To further assess the prognostic nature of the LLV group, the impact of the number of times 
patients had vRNA <50 copies was explored. Of the LLV group, 63 patients had only one 
vRNA response <50 copies/mL during weeks 16–48 (LLV1), and 48 patients had multiple 
vRNA responses <50 copies/mL during the same period (LLV2; the number of responses 
<50 copies/mL was 2 in 21 patients, 3 in 17 patients, 4 in six patients, and 5 in four 
patients). Virologic response rates (after week 48) and the mean change from baseline in 
CD4 counts through week 240 were higher in the LLV1 group than in the LLV2 group, 
although there was substantial overlap in the 95% confidence intervals (Suppl. Figures S1-
S3). The TLOVR analysis also suggested there may be a difference favoring the LLV1 
group (Suppl. Figure S4), although LLV subgroup was not a significant predictor of TLOVR 
in the Cox regression (LLV1 vs. LLV2, log-rank, p=0.07). The other factors examined in 
this analysis also were not significant predictors of TLOVR.
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We explored the relationship between late outcomes and early virologic response among 
patients who received raltegravir for at least 48 weeks in the BENCHMRK studies. Patients 
were categorized by their early virologic response (vRNA levels at weeks 16–48) as 
continuously suppressed (CS, all measurements <50 copies/mL), low-level viremia (LLV, 
all measurements < 400 copies/mL and at least one <50 copies/mL), or not suppressed (NS, 
at least one measurement <400 copies/mL). Patients with low-level viremia had higher 
vRNA levels and lower CD4 cell counts at baseline than patients with continuous 
suppression. However, rapid viral decay (defined as vRNA <50 copies/mL at least once 
before week 12) was the only factor found to be significantly associated with first-year viral 
response category in the multiple regression analysis. Patients with continuous suppression 
were significantly more likely to have demonstrated rapid virologic decay (94%) compared 
to those with low-level viremia (64%) and those who were not suppressed (43%). Patients 
with low-level viremia demonstrated durable efficacy responses through 5 years of 
treatment, showing favorable virologic and immunologic outcomes that were similar to 
those in patients with continuous suppression, including no significant difference in TLOVR 
(vRNA ≥400 copies/mL) and a low rate of treatment-emergent resistance mutations (4 of 14 
patients with virologic failure). Although previous analyses [15,16] suggested a significant 
difference (p<0.05) in TLOVR between the CS and LLV groups at week 156 (3 years) and 
week 192 (4 years), the overall data through week 240 did not support as strong a difference 
(p=0.11).
Low-level viremia may not be a marker of incomplete suppression of ongoing viral 
replication in highly treatment-experienced patients after initiation of combination therapy 
that includes at least one fully active agent. The fact that only a minority of these raltegravir-
treated patients with low-level viremia during the first year had subsequent overt virologic 
failure despite limited activity of the OBT regimen suggests that ongoing viral replication 
may not be the source of the viremia in many of these patients. Emergence of resistance to 
raltegravir was also uncommon and similar to the continually suppressed group, supporting 
the hypothesis that ongoing rounds of replication are not the predominant source of early 
low-level viremia.
Raltegravir-containing regimens are associated with significantly longer first-phase viral 
decay (d1) and transition to second-phase decay (d2) at lower vRNA levels than efavirenz-
containing regimens [17,18]. Andrade and colleagues conclude that the rapid viral decay 
observed with raltegravir is due to the longer duration of d1, which may reflect a reduction 
in the pool of cells that contribute to d2 [17]. In our study, the observation that rapid viral 
decay was the only significant predictor of vRNA response category (CS>LLV>NS) 
suggests that patients with low-level viremia may have a larger reservoir contributing to 
viral decay, as the transition from the first to second phase decay was more likely to occur at 
a vRNA level <50 copies/mL and therefore lead to a longer time to suppression to <50 
copies/mL. In these patients, release of virus during the 2nd or 3rd phase of viral decay may 
result in vRNA levels <50 copies/mL that do not represent ongoing replication. The 
substantially higher median baseline viral load in the LLV group compared to the CS group, 
with a larger percentage with vRNA <100,000 copies/mL (42.3 vs 18.6%), also supports the 
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concept that early low-level viremia may represent release from a larger reservoir, as pre-
therapy vRNA has been clearly associated with reservoir size on therapy [19–22]. The fact 
that rapid viral decay was associated with initial complete suppression but not long-term 
response may be because patients in both the CS and LLV categories had full suppression of 
HIV-1 replication. However, given our small sample size and retrospective analysis design, 
an association between rapid viral decay and longer term suppression may have been 
missed.
Differences in adherence could provide an explanation as to why some patients have 
continuous suppression and others have low-level viremia. Acknowledging the limitations of 
self-reported adherence, the adherence rates in this study were remarkably similar between 
the CS and LLV groups (Table 2) and are therefore an unlikely explanation for the 
differences observed in the first 48 weeks between these two groups. In contrast, patients in 
the NS group had poorer self-reported adherence and were substantially more likely to have 
virologic or efficacy failure and evolution of raltegravir resistance, all suggestive of ongoing 
rounds of replication as a cause of the higher level of early viremia in this group. Finally, it 
is possible that the difference between the CS group and the LLV group is based 
predominantly on the imprecision of the assays at these low levels [8]. Certainly assay 
variability at low levels of vRNA may contribute to single episodes of vRNA <50 
copies/mL. However, the LLV group in this study seems biologically different from the CS 
group, with higher baseline vRNA, lower baseline CD4 cells counts, and a lower likelihood 
of rapid vRNA suppression. Within the LLV group, patients who had more than one vRNA 
measurement <50 copies/mL during weeks 16–48 did not appear to have substantially 
different outcomes than those with a single vRNA value <50 copies/mL, although small 
numbers make these estimates less precise and proportion of patients with loss of virologic 
response was higher in this group.
The clinical implications of our post hoc analysis should be interpreted cautiously. Our 
observations raise the possibility that low-level viremia that occurs in treatment-experienced 
patients in the year following initiation of therapy may not be evidence of incomplete 
suppression of ongoing HIV-1 replication and impending virologic failure in all patients. 
This level of vRNA may not require a change in therapy, especially in patients who have 
limited further treatment options. In this study raltegravir was frequently the only fully 
active agent in the treatment regimen and ongoing replication would be expected to lead to 
emergence of integrase inhibitor resistance, an uncommon result in our patients with early 
low-level viremia. In addition, long-term CD4 increases were very similar in patients with 
low-level viremia who continued the same therapy and those with continued suppression. 
Our results reflect the DHHS guidelines which suggest that a change in therapy may not be 
necessary in patients with low-level viremia [23], although the DHHS guidelines use a 
confirmed viral load <200 copies/mL as the definition for virologic failure, while we used an 
upper level of 400 copies/mL in our definition of low-level viremia. A more stringent cutoff 
of 200 copies/mL would likely further minimize the differences between the CS and LLV 
groups. In the context of large clinical cohorts, others have shown that low-level viremia is 
associated with subsequent virologic failure, although the timing of the low-level viremia in 
relationship to when therapy was initiated may be important [24–27]. Resistance testing 
during periods of low-level viremia may help to understand the consequences of the viremia 
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[13,28,29] and allow for optimization of therapy [30,31], but resistance testing when vRNA 
is < 400 copies/mL may not be available to all clinicians. Therefore, treatment-experienced 
patients with low-level viremia in the year following a change in therapy prompted by 
virologic failure should be followed carefully with serial vRNA measurements. Our data 
suggest that treatment-experienced patients on a raltegravir-based regimen with early low-
level viremia may have long-term virologic and immunologic benefit when their therapy is 
maintained.
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Efficacy outcomes by first-year vRNA response category: (A) % of patients with vRNA <50 
copies/mL, (B) % of patients with vRNA <400 copies/mL, and (C) change from baseline in 
CD4 cell count.
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Time to loss of virologic response (TLOVR, ≥400 copies/mL) by first-year vRNA response 
category
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Table 1













Plasma HIV RNA (copies/mL)
  Geometric Mean 22770 60592 82652
  Median (range) 25800 (200-574000) 78900 (441-750000) 102000 (619-750000)
    ≤ 50,000 126 (63.3) 40 (36.0) 23 (36.5)
    50,000 – 100,000 36 (18.1) 24 (21.6) 7 (11.1)
    > 100,000 37 (18.6) 47 (42.3) 33 (52.4)
CD4 Cell Counts (cells/mm3)
  Mean 188 138 110
  Median (range) 166 (2 to 792) 101 (1 to 740) 69 (1 to 469)
    ≤ 50 33 (16.6) 41 (36.9) 29 (46.0)
    > 50 and ≤ 200 81 (40.7) 43 (38.7) 22 (34.9)
    > 200 84 (42.2) 27 (24.3) 12 (19.0)
CD4%, median (range) 11 (0 to 46) 9 (0 to 30) 5 (0 to 26)
CD8 Cell Counts (cells/mm3)
  Median (range) 887 (167 to 2605) 729 (46 to 2296) 642 (69 to 2530)
CD8%, median (range) 62 (26 to 89) 61 (11 to 86) 62 (21 to 83)
CD4/CD8 Ratio
  Median (range) 0.18 (0.01 to 1.23) 0.14 (0.01 to 0.66) 0.07 (0.01 to 0.91)
Number of ARTs in OBT
  Median (range) 4.0 (1 to 6) 4.0 (2 to 6) 4.0 (2 to 7)
Number of Active PI in OBT by Phenotypic Resistance Test†
      0 63 (31.7) 31 (27.9) 23 (36.5)
      1 or more 129 (64.8) 77 (69.4) 37 (58.7)
Phenotypic Sensitivity Score (PSS)‡
      0 25 (12.6) 8 (7.2) 8 (12.7)
      1 58 (29.1) 37 (33.3) 21 (33.3)
      2 66 (33.2) 47 (42.3) 12 (19.0)
      3 or more 41 (20.6) 15 (13.5) 18 (28.6)


























Genotypic Sensitivity Score (GSS)‡
      0 33 (16.6) 21 (18.9) 16 (25.4)
      1 76 (38.2) 52 (46.8) 24 (38.1)
      2 60 (30.2) 31 (27.9) 10 (15.9)
      3 or more 27 (13.6) 6 (5.4) 11 (17.5)
†
For patients missing baseline genotypic and/or phenotypic test results, "number of active PI in OBT determined by phenotypic resistance test" =1 
or more if first time use darunavir in OBT.
‡
PSS GSS were defined as the total oral ARTs in OBT to which a patient's viral isolate showed phenotypic sensitivity and genotypic sensitivity, 
respectively, based upon phenotypic and genotypic resistance tests. Enfuvirtide use in OBT in enfuvirtide-naïve patients was counted as one active 
drug in OBT and added to the GSS and PSS. Darunavir use in OBT in darunavir-naïve patients was counted as one active drug in OBT and added 
to the PSS and GSS.
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Table 2







Percent Compliance† n (%) n (%) n (%)
100% 158 (79.4) 88 (79.3) 44 (69.8)
99 to 90% 39 (19.6) 21 (18.9) 15 (23.8)
89 to 80% 2 (1.0) 2 (1.8) 1 (1.6)
79 to 70% 0 0 2 (3.2)
<70% 0 0 1 (1.6)
†
Percent compliance was calculated as: [number of days on therapy / number of days should be on therapy] * 100.
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Table 3










Completed 240 weeks of treatment 133 (66.8) 69 (62.2) 19 (30.2)
Discontinued due to virologic failure† 7 (3.5) 10 (9.0) 15 (23.8)
Discontinued due to lack of efficacy‡ 4 (2.0) 3 (2.7) 13 (20.6)
Discontinued for other reasons 55 (27.6) 29 (26.1) 16 (25.4)
  Clinical adverse event 10 (5.0) 6 (5.4) 3 (4.8)
  Consent withdrawn 12 (6.0) 8 (7.2) 7 (11.1)
  Lost to follow-up 6 (3.0) 2 (1.8) 2 (3.2)
  Other reasons†† 27 (13.6) 13 (11.7) 4 (6.3)
†
Virologic failure was considered to have occurred if vRNA did not decrease to <400 copies/mL or by >1 log10 copies/mL from baseline; if 
vRNA increased by >1 log10 copies/mL from the nadir level on two consecutive measurements; or if vRNA was ≥400 copies/mL on two 
consecutive measurements after having been <400 copies/mL.
‡
Lack of efficacy was determined by the site investigator.
††
Includes the following: protocol deviation, did not enter extension phase, moved or relocated, or clinical trial was terminated at the site.
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